T-cell biomarkers show promise for CAR-T therapy in CLL, but is it enough?
University of Pennsylvania researchers’ recent announcement of the identification of T cell biomarkers...
Trending:
Most Read
Latest Content
Novartis closes $8.7bn acquisition of AveXis
Novartis has completed the acquisition of clinical-stage gene therapy company AveXis for a total consideration of $8.7bn.
Eiger expands lonafarnib licensing deal with Merck
Eiger BioPharmaceuticals has expanded a licensing agreement with Merck to cover the right to develop lonafarnib to treat Hutchinson-Gilford progeria syndrome (HGPS or progeria).
T-cell biomarkers show promise for CAR-T therapy in CLL, but is it enough?
University of Pennsylvania researchers’ recent announcement of the identification of T cell biomarkers that could predict with 100% accuracy those chronic lymphocytic leukemia (CLL) patients who would experience a complete clinical response to chimeric antigen receptor (CAR)-T cell therapy is an exciting advancement.
Lilly to buy Canada’s AurKa Pharma for $110m
Eli Lilly has signed an agreement to acquire all shares in Canada-based cancer drug developing company AurKa Pharma for an upfront payment of $110m.
Biotech M&A: will the 2018 surge last?
Analysts are predicting a surge of M&A activity in the biotech space, with large pharma firms looking to pad their pipelines with new acquisitions, US tax reform freeing up cash flow, and rapidly-consolidating US healthcare buyers likely to put more pressure on the price of existing drugs. How is the biotech M&A landscape likely to develop over the course of 2018?
CPHI experts: 90% of current pipeline APIs are poorly soluble
Advances in solubility and surface area are being driven by a massive change in the solubility of pipeline APIs, claimed industry experts at the Solubility Enhancement and Improving Oral Bioavailability panel of the Convention on Pharmaceutical Ingredients (CPHI) North America conference in Philadelphia, Pennyslvania, US, on Tuesday, April 24,. These experts estimated that 90% of the current drug pipeline is poorly soluble.
New fund will address misuse of drugs in UK care homes
The UK National Health Service recently announced a £20m investment to fund 180 pharmacists and 60 pharmacy technicians to work in care homes.
United Therapeutics to purchase SteadyMed in $216m deal
US-based biotechnology company United Therapeutics has signed a definitive merger agreement to buy SteadyMed for a total consideration of $216m, including $75m contingent.
Takeda chases after its largest deal yet
Takeda’s possible $65B takeover of Shire could be the largest deal value in pharma this year.
India teams up with World Bank to boost healthcare sector
The Government of India has entered a $125m agreement with the World Bank to advance the country's biopharmaceutical and medical devices industry.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
